Small (Weinheim an der Bergstrasse, Germany)Apr 27, 2026

An mRNA Tumor Vaccine Combining Tumor Antigen and Angiotensin II May Boost Anti-Tumor Immunity Through Key Immune Cells

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Apr 28, 2026

Abstract

An antigen-angiotensin II (ANG II) fusion mRNA nanovaccine demonstrates significant tumor inhibition in mouse models.

The nanovaccine enhances the immune response by promoting the maturation of dendritic cells.
Increased type 1 conventional dendritic cell (cDC1) populations are associated with improved antigen presentation.
Vaccination effectively inhibits tumor growth across multiple mouse tumor models.
Tumor growth inhibition is significantly reduced in mice lacking cDC1, indicating their role in the immune response.
This approach may improve the effectiveness of mRNA-based tumor vaccines by enhancing CD8T cell immunity.

Simplified

mRNA-based tumor vaccines have shown great potential as a promising immunotherapeutic approach with encouraging preclinical and clinical results. However, how to enhance the antigen presentation efficiency of mRNA-encoded tumor antigens and the intensity of vaccine-induced CD8T cell response remains a great challenge. In this study, an antigen-angiotensin II (ANG II) fusion mRNA nanovaccine that can enhance the immunogenicity of tumor antigens to promote CD8T cell immunity for effective tumor inhibition is developed. Furthermore, this mRNA nanovaccine is delivered by lipid nanoparticles (LNPs) composed of cationic lipid-like material C1 and L-phenylalanine-based poly (ester amide) 8p4, which promotes the maturation of dendritic cells (DCs) and increases the type 1 conventional DC (cDC1) subpopulation, together enhancing the antigen presentation function of DCs for eliciting potent antigen-specific CD8T cell response. Vaccination with the antigen-ANG II mRNA nanovaccine expressing different tumor antigens effectively inhibited tumor growth on multiple mouse tumor models, which was greatly compromised in the cDC1-deficient Batf3mice. Overall, this work provides an antigen-ANG II fusion mRNA tumor nanovaccine platform with remarkable antitumor efficacy via triggering cDC1-mediated CD8T cell response. + + + -/-+

Full Text

Full text is available at the source.

View Full Text ↗

An mRNA Tumor Vaccine Combining Tumor Antigen and Angiotensin II May Boost Anti-Tumor Immunity Through Key Immune Cells

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief